Back to results
US 2019/0167694 A1Published application
New therapeutics uses
AssigneeNovartis AG
InventorsYong Jia, GERALD LELAIS, THOMAS HERBERT MARSILJE, III, ANDREW TODD MILLER, SHAILAJA KASIBHATLA
Life of this patent
Estimating the term…
Abstract
New uses of an EGFR inhibitor are disclosed. Methods of treatment using the EGFR inhibitor are also disclosed.
Claims20
1-2. (canceled)
A method for the treatment of a T cell-mediated autoimmune disease comprising administering a therapeutically effective amount of the compound (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1 H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (nazartinib), or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
(canceled)
Dependencies are inferred from the claim text.